Compare Bank of New York Mellon Corp (BNY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Summit Therapeutics Inc — how do they compare? Bank of New York Mellon Corp trades at $163.67 (market cap $108.78B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Bank of New York Mellon Corp is far larger — about 9× Summit Therapeutics Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BNY | SMMT | |
|---|---|---|
Market Cap | $108.78B | $12.06B |
Sector | Financials | Health |
52-Week High | $162.35 | $26.98 |
52-Week Low | $101.00 | $12.55 |
Dividend Yield | 1.38% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $162.98, up 2.22% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported record Q2 2026 results with EPS of $2.46, surpassing estimates, and announced a strategic collaboration to advance digital asset infrastructure. Revenue growth is steady, rising to $19.76B in 2025, with a net income margin of 29.96%.
Outlook remains positive with a consensus price target of $170.36, though risks include high investing cash outflows and competitive pressures. The stock's current price is near the consensus target, suggesting limited upside without further catalysts. Institutional sentiment is mixed, with 45% buy ratings and 55% hold.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
